Pluri (NASDAQ:PLUR) Trading Up 3.3% – Here’s Why

Shares of Pluri Inc. (NASDAQ:PLUR) rose 3.3% during mid-day trading on Friday . The stock traded as high as $2.0093 and last traded at $1.86. Approximately 37,334 shares were traded during mid-day trading, a decline of 9% from the average session volume of 41,117 shares. The stock had previously closed at $1.80.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 7th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Pluri Trading Up 3.3%

The firm has a market cap of $20.07 million, a P/E ratio of -0.41 and a beta of 0.64. The company’s 50 day simple moving average is $2.31 and its 200-day simple moving average is $2.99.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.11. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.66 million.

Institutional Investors Weigh In On Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC bought a new stake in shares of Pluri Inc. (NASDAQ:PLUR) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned about 0.14% of Pluri at the end of the most recent quarter. 16.59% of the stock is owned by hedge funds and other institutional investors.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.